Kitiya Rujimongkon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kitiya Rujimongkon has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Wannarasmi Ketchart
Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
2 shared publications Chanoknun Boonyaratsewee
Affiliation Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand
1 shared publication- Chanoknun Boonyaratsewee
Department of Chemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand
1 shared publication Kantasorn Horpratraporn
Affiliation Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
1 shared publicationOnrapak Reamtong
Department of Molecular Tropical Medicine and Genetic, Faculty of Tropical Medicine, Mahidol University, Ratchawithi Road, Ratchathewi, Bangkok, 10400, Thailand
1 shared publicationPatthamapon Adchariyasakulchai
Affiliation Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
1 shared publication
Latest Publications
- 8 June 2026
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 24 (27) , 5726-5736
Synthesis of meta -substituted phenols and 1-estradiol conjugated analogues of suberoylanilide hydroxamic acid (SAHA)
A facile synthesis of challenging meta-substituted phenols. 1-Substituted estradiols were prepared for the first time. New analogues of the anticancer drug SAHA were obtained.
- 8 June 2026
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 24 (27) , 5726-5736
Synthesis of meta -substituted phenols and 1-estradiol conjugated analogues of suberoylanilide hydroxamic acid (SAHA)
A facile synthesis of challenging meta-substituted phenols. 1-Substituted estradiols were prepared for the first time. New analogues of the anticancer drug SAHA were obtained.
- Open Access
- 30 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0348260
Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells
Ivermectin (IVM), initially developed as an antiparasitic drug, has recently demonstrated notable anticancer activity in several malignancies, including breast cancer. Our previous work showed that IVM inhibited cell proliferation and invasion in breast cancer cells, primarily through modulation of the Wnt signaling pathway. Preliminary results further indicated that combining IVM with tamoxifen enhanced its antiproliferative effects in endocrine-resistant breast cancer cells, suggesting a potential role in overcoming drug resistance. To further clarify IVM’s mechanism in the context of endocrine resistance, this study investigated its effects on estrogen receptor-positive (ER⁺) and endocrine-resistant breast cancer cells. IVM significantly suppressed estrogen-induced proliferation and downregulated key resistance-associated markers, including ER and HER2. Additionally, IVM treatment markedly reduced ERK, a downstream effector linked to HER2 and TGF-β signaling. This inhibition was accompanied by a decrease in phosphorylated SMAD2 (pSMAD2) within the TGF-β pathway, while levels of SMAD4—a factor associated with favorable prognosis in endocrine resistance—were maintained. Collectively, these findings highlight IVM’s potential as a repurposed therapeutic agent, with the dual capacity to prevent endocrine resistance in ER⁺ breast cancer and to enhance anti-hormonal therapies in resistant cases.
- 30 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0348260
Open AccessIvermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells
Ivermectin (IVM), initially developed as an antiparasitic drug, has recently demonstrated notable anticancer activity in several malignancies, including breast cancer. Our previous work showed that IVM inhibited cell proliferation and invasion in breast cancer cells, primarily through modulation of the Wnt signaling pathway. Preliminary results further indicated that combining IVM with tamoxifen enhanced its antiproliferative effects in endocrine-resistant breast cancer cells, suggesting a potential role in overcoming drug resistance. To further clarify IVM’s mechanism in the context of endocrine resistance, this study investigated its effects on estrogen receptor-positive (ER⁺) and endocrine-resistant breast cancer cells. IVM significantly suppressed estrogen-induced proliferation and downregulated key resistance-associated markers, including ER and HER2. Additionally, IVM treatment markedly reduced ERK, a downstream effector linked to HER2 and TGF-β signaling. This inhibition was accompanied by a decrease in phosphorylated SMAD2 (pSMAD2) within the TGF-β pathway, while levels of SMAD4—a factor associated with favorable prognosis in endocrine resistance—were maintained. Collectively, these findings highlight IVM’s potential as a repurposed therapeutic agent, with the dual capacity to prevent endocrine resistance in ER⁺ breast cancer and to enhance anti-hormonal therapies in resistant cases.
- Open Access
- 1 July 2021
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 11 (6) , 587-597
The therapeutic effects of Bombyx mori sericin on rat skin psoriasis through modulated epidermal immunity and attenuated cell proliferation
- 1 July 2021
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 11 (6) , 587-597
Open AccessThe therapeutic effects of Bombyx mori sericin on rat skin psoriasis through modulated epidermal immunity and attenuated cell proliferation